An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case that Moderna had breached the U.K. marketing code. Initially, the PMCPA ...

We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

The vaccines’ effect on inflammation-promoting cells might help to explain why the jabs protect against severe disease.

The following first ran on CounterPunch at the height of the COVID pandemic in January of 2022. Are anti-vaccine ...

BRITS are being urged to stay at home and mask up when venturing outside after a “worrying” surge in norovirus cases. While ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands among Wednesday’s ...